Thermo Fisher Scientific to Co-develop a Global Companion Diagnostic for Low-grade Glioma with Agios Pharmaceuticals June 9, 2020June 9, 2020 by / Share This.....LinkedinTwitterFacebookGoogleEmailAgreement calls for identifying IDH gene mutations using Oncomine Precision Assay and the Ion Torrent Genexus System, a new turnkey, next-generation sequencing solution Related News: Ellutia introduces fully automated total nitrosamine…Providing a New Tool for Developing Manufacturing…FDA Approves NGS-Based Companion Diagnostic for EGFR…U.S. FDA approves Foundation Medicine’s…Roche receives FDA approval for first companion…Thermo Fisher Scientific to Present at Morgan…
